Home
Technology
Pipeline
Intranasal Naloxone
Intranasal Epinephrine
About us
Contact
News
Menu
Home
Technology
Pipeline
Intranasal Naloxone
Intranasal Epinephrine
About us
Contact
News
Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis
Click Here
Share this post
Previous
Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine
Next
Nasus Pharma to Present Positive Clinical Results from Recent studies of FMXIN002 (NS002) Intranasal Epinephrine at the 2025 AAAAI Annual Meeting
